SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, HorseShoe Man, sup105
Search This Board:
Last Post: 7/31/2015 3:21:47 PM - Followers: 568 - Board type: Free - Posts Today: 11




Ticker - MCET (U.S. Reporting: SEC Filer) 

Estimated outstanding shares: 5.0+/- Billion a/o July 2015

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate  


Discovery Optimization    

Preclinical Development    

Phase 1    

Phase 2/b   

Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
 Office: (401) 762-0045

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations
P. (401) 762-0045

W. Gerald Newmin, Chairman and Chief Executive Officer
(941) 637-9883
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.

Dr. Steve Chang Ph. D., Director

Dr. Stephen Chang has served as a director of the Company since June 2004.  Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008.  Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006.  Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005.  Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004.  Dr. Chang has also held senior management positions at Chiron and Viagene.  Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications.  Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine.  Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.

Grant Miller, Director

Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.

Thomas A. Page, Director

Mr. Thomas Page has served as a director of the Company since September 2003.  Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy).  Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and  held one or more of these positions until his retirement in 1998.  Mr. Page joined SDG&E in 1978 as executive vice president and COO.  In 1981, he was elected president and CEO and added the chairmanship in 1983.  Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research.  He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures.  Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University.  Mr. Page has been licensed as an engineer and as a certified public accountant (CPA).  Mr. Page also serves on the University of California Presidents Council on the National Laboratories.

Edward Sigmond, Director

Mr. Edward Sigmond has served as a director of the Company since May 2000.  Mr. Sigmond has been in sales, marketing and operations management for the past 20 years.  Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997.  Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved.  Mr. Sigmond studied Marketing and Chemistry at Duquesne University.

Alan Tuchman, M.D.

Dr. Tuchman is concurrently in private practice and is Clinical Professor of Neurology at New York Medical College.  He is also the Principal of a healthcare and neuroscience consulting firm.  From 1997 to 2001, Dr. Tuchman was Senior Vice President of Equity Research for Oscar Gruss & Son (Member of the New York Stock Exchange), New York, New York, where he conducted investment research in medical and biotechnology and helped develop marketing strategies for healthcare companies.  Prior to this, he was Vice Dean of Clinical Affairs for New York Medical College where he developed and directed clinical care and medical education policy for 29 affiliated hospitals and served as Professor and Vice Chairman and Program Director for Neurology Residency in the Department of Neurology at the same institution.  At the Lincoln Medical and Mental Health Center, Dr. Tuchman held the positions of Medical Director for the 560-bed hospital from 1990 to 1991 and Director of the Department of Neurology from 1979 to 1994.  Serving in the United States Air Force as Major, he was Chief of Neurology Service for a 16-state region.  Dr. Tuchman earned his B.S. in Chemistry in 1968 from the City College of New York, his M.D. in 1972 from the University of Cincinnati College of Medicine, and his MBA from Columbia University in 1996. He completed his internship at New York Medical College and his residency at the Mount Sinai Hospitals Department of Neurology.  Dr. Tuchman was a clinical fellow in multiple sclerosis at the Albert Einstein College of Medicine Department of Neurology.  Dr. Tuchman is certified by the American Board of Psychiatry and Neurology and the American Society of Neurorehabilitation and is licensed in New York, New Jersey and Ohio.  Dr. Tuchman served as the President of the Epilepsy Society of Southern New York from 1987 1992.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:10:34 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:09:13 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:07:11 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:05:40 PM
MCET News: Quarterly Report (10-q) 07/16/2015 06:06:29 AM
#39718  Sticky Note sup105 03/12/15 02:33:46 PM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#40667   Who ever want's 2's here is your shot Dip66 07/31/15 03:21:47 PM
#40666   I have a little nest egg here and Dip66 07/31/15 10:53:48 AM
#40665   It does appear to be a bullshit little veto 07/31/15 10:32:09 AM
#40664   I doubt it. The MM's are not going MyDogBuster 07/31/15 10:15:10 AM
#40663   So I still might get back in at HorseShoe Man 07/31/15 10:00:19 AM
#40662   If you look at the Form 4's you MyDogBuster 07/31/15 09:26:25 AM
#40661   With 50Mil in debt and over 5billion O/S Dip66 07/31/15 09:23:58 AM
#40660   I'm sure they would buy in now. Now HorseShoe Man 07/31/15 08:54:21 AM
#40659   It may be a form of insider trading. ctvette2003 07/31/15 07:51:07 AM
#40658   I guess now that the company is actually HorseShoe Man 07/31/15 07:34:34 AM
#40657   How can this be fair? All these director's HorseShoe Man 07/31/15 06:58:47 AM
#40656   Outstanding shares is 5,000,948,700 as of Jul 8, 2015 MyDogBuster 07/30/15 09:35:39 PM
#40655   i sure hope they aren't trying to lure Dip66 07/30/15 09:24:06 PM
#40654   Insider buying 10M shares, its only 4k buy ctvette2003 07/30/15 07:33:32 PM
#40653   Have I missed something? -- zero (0) volume -- veto 07/30/15 05:23:04 PM
#40652   What's the likely hood of a RS here? Jeppy D 07/30/15 01:18:26 PM
#40651   Don't sell yourself short, might be able to Dip66 07/30/15 11:37:52 AM
#40650   hope so then my order will fill for HorseShoe Man 07/30/15 10:14:24 AM
#40649   I'm predicting we will see .0001's by Friday. Dip66 07/29/15 07:10:29 PM
#40648   Reread buddy, I was making fun of Semperfi's ctvette2003 07/29/15 12:09:41 PM
#40647   Nonsense post!!!! Check yourself mental health hospital are eshety 07/29/15 11:57:08 AM
#40646   Conspiracy theory, really? ctvette2003 07/28/15 05:31:49 PM
#40645 Semperfifi 07/28/15 05:02:05 PM
#40644   Yup. Only a matter of time before La Dip66 07/28/15 12:28:36 PM
#40643   Then we come to the proverbial elephant in simon wagstaff 07/28/15 07:52:40 AM
#40642   With the dumping going on lately and no Dip66 07/27/15 12:05:22 PM
#40641   I'm not saying a single thing because my HorseShoe Man 07/27/15 07:45:14 AM
#40640   I don't know. bontooth 07/26/15 02:59:46 AM
#40639   fill fill fill!!!! HorseShoe Man 07/24/15 09:52:17 AM
#40638   $MCET - I found this: Dip66 07/23/15 10:30:14 AM
#40637   what new number did mcet file with a sec? HorseShoe Man 07/23/15 09:26:06 AM
#40636   $MCET - Good luck with that grabbed all Dip66 07/22/15 12:02:49 PM
#40635   Just fill my order at .0002 then run it HorseShoe Man 07/21/15 08:47:32 PM
#40634   Still worth .0003 a share. At best. simon wagstaff 07/21/15 09:07:22 AM
#40633   MultiCell Technologies, Inc. (“MultiCell”), operates two subsidiaries, Xenogenic Dip66 07/20/15 03:19:49 PM
#40632   You are incorrect, you have to be insane simon wagstaff 07/20/15 01:08:23 PM
#40631   $MCET is so under the radar it's insane. Dip66 07/20/15 12:29:43 PM
#40630   JULY 17, 2015 MultiCell Technologies, Inc. Market Dip66 07/17/15 08:50:52 PM
#40629   $MCET 18M Volume 3X4 packed up! Something big Dip66 07/17/15 03:44:38 PM
#40628   the 10 q says 7 billion. The dead cat bouncer 07/17/15 03:08:20 PM
#40627   Thats what I did, grabbed 3.5M this morning. ctvette2003 07/17/15 03:05:37 PM
#40626   Maybe I should buy back in before something happens? HorseShoe Man 07/17/15 02:06:24 PM
#40625   I think the company is ramping up for Dip66 07/17/15 01:52:43 PM
#40624   Might have been a good filing but didnt ctvette2003 07/17/15 01:48:31 PM
#40623   O/S in last filing. Dip66 07/17/15 12:43:49 PM
#40622   Looking good! Is this the first time in Dip66 07/17/15 12:43:34 PM
#40621   Does anyone have an accurate outstanding share count? ztek 07/17/15 12:29:40 PM
#40620   congratulations to those who are still holding MCET's HorseShoe Man 07/17/15 11:38:15 AM
#40619   I read the whole 10 q and it The dead cat bouncer 07/16/15 10:07:51 PM
#40618   At these low prices if the company was Dip66 07/16/15 09:58:42 PM